PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-2 (2)
 

Clipboard (0)
None
Journals
Authors
more »
Year of Publication
Document Types
1.  Cost effectiveness of interferon α or peginterferon α with ribavirin for histologically mild chronic hepatitis C 
Gut  2006;55(9):1332-1338.
Background
For patients with mild chronic hepatitis C the cost effectiveness of antiviral therapy is unknown.
Aims
To assess whether antiviral therapy (either interferon α or peginterferon α combined with ribavirin) is cost effective at a mild stage compared with waiting and only treating those cases who progress to moderate disease.
Patients
Cases with mild chronic hepatitis C.
Methods
A cost effectiveness model which estimates long term costs and outcomes for patients with mild chronic hepatitis C. The model uses effectiveness and cost data from the UK mild hepatitis C randomised controlled trial, combined with estimates of disease progression and cost from observational studies.
Results
Antiviral treatment at a mild rather than a moderate stage improved outcomes measured by quality adjusted life years (QALYS) gained. The mean cost per QALY gained from antiviral treatment with interferon α‐2b and ribavirin, compared with no treatment at a mild stage, was £4535 ($7108) for patients with genotype non‐1 and £25 188 ($39 480) for patients with genotype 1. Providing peginterferon α‐2b and ribavirin at a mild rather than a moderate stage was also associated with a gain in QALYS; the costs per QALY gained were £7821 ($12 259) for patients with genotype non‐1 and £28 409 ($44 528) for patients with genotype 1.
Conclusions
For patients with chronic hepatitis C, it is generally more cost effective to provide antiviral treatment at a mild rather than a moderate disease stage. For older patients (aged 65 years or over) with genotype 1, antiviral treatment at a mild stage is not cost effective.
doi:10.1136/gut.2005.064774
PMCID: PMC1860032  PMID: 15994216
cost effectiveness model; cost analysis; antiviral therapy
2.  An incomplete form of acanthosis nigricans 
Gut  1962;3(3):269-272.
The authors report a variation of the clinical picture of acanthosis nigricans in two patients with carcinoma of the stomach.
Images
PMCID: PMC1413343  PMID: 13989672

Results 1-2 (2)